Radiation Oncology

ASCO 2025

Questions discussed in this category

What are your top takeaways in Head & Neck Cancers from ASCO 2025?

3 Answers available

What are your top takeaways in Neuro Oncology from ASCO 2025?

2 Answers available

What are your top takeaways in Gyn Cancers from ASCO 2025?

2 Answers available

What are your top takeaways in GU Cancers from ASCO 2025?

6 Answers available

What are your top takeaways in Breast Cancer from ASCO 2025?

8 Answers available

What are your top takeaways from ASCO GU 2025?

6 Answers available

Papers discussed in this category

The Lancet. Oncology, 2025 Feb 13

Overall survival and quality of life with [Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Sep 21

Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO).

Annals of oncology : official journal of the European Society for Medical Oncology, 2025 Feb 07

Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial.

N Engl J Med,

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.

Lancet Oncol., 2020 Mar 12

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.

N. Engl. J. Med., 2017-07-27

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

International journal of radiation oncology, biology, physics, 2014-03-01

Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis.

Annals of oncology : official journal of the European Society for Medical Oncology, 2025 May 30

Dostarlimab and niraparib in primary advanced ovarian cancer.

Lancet (London, England), 2025 Jun 02

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.

Annals of oncology : official journal of the European Society for Medical Oncology, 2025 Jun 02

Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses.

Neuro-oncology, 2013-10

Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.

Related Topics in Radiation Oncology